Merck upgraded to Overweight from Equal Weight at Morgan Stanley
Upside potential improves; favorable risk-reward.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Upside potential improves; favorable risk-reward.
What happened, with direct paths to the underlying reporting
Morgan Stanley upgrades MRK to Overweight; target $179; price $152.22.
Target: $179
Posted price: $152.22
Analyst firm: Morgan Stanley
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.